Victrex plc

Victrex plc

VTXPF
Victrex plcUS flagOther OTC
8.18
USD
- -
- -
712.68MMarket Cap
Victrex plc
VTXPF
(Other OTC)

Recent

price

8.18

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
2.29
2.59
2.62
2.63
2.98
3.1
2.96
3.39
3.8
3.34
3.06
3.59
3.92
3.53
3.41
3.41
Revenue per Share
0.65
0.85
0.86
0.86
0.95
0.98
0.97
1.16
1.29
1.07
0.63
0.84
0.88
0.71
0.2
0.32
Basic EPS, GAAP
0.88
0.68
0.47
0.47
0.38
0.55
0.67
1.18
1.39
0.67
0.51
0.98
0.4
0.04
0.59
0.57
Free Cash Flow per Basic Share
0.2
0.77
0.33
0.39
0.44
0.95
0.47
0.47
1.23
1.42
0.46
0.6
1.1
0.6
0.6
0.6
Dividend per Share
2.22
2.32
2.84
3.29
3.74
3.78
4.18
5.02
5.14
4.73
4.86
5.15
4.93
4.99
4.59
4.33
Book Value per Share
2.43
2.54
3.11
3.6
4.05
3.97
4.29
5.24
5.38
5.04
5.26
5.62
5.41
5.55
5.11
4.77
Tangible Book Value per Share
83
83
84
84
85
85
85
85
86
86
86
87
87
87
87
87
Basic Weighted Avg Shares
190
216
220
222
253
264
252
290
326
288
264
311
341
307
296
296
Sales/Revenue/Turnover
39.53
43.47
42.77
42.36
40.46
40.34
39.95
38.97
38.93
36.65
28.73
30.01
25.95
23.84
15.46
13.43
Operating Margin (%)
9
9
10
10
10
13
16
18
18
17
21
22
22
22
23
25
Depreciation Expense
54
71
72
73
80
84
82
100
111
92
54
73
76
62
17
28
Net Income, GAAP
27.9
24.42
23.92
22.94
21.91
21.52
17.75
10.36
13.25
11.75
14.65
21.3
13.91
15.86
32.48
26.33
Effective Tax Rate (%)
28.5
32.99
32.71
32.85
31.75
31.69
32.7
34.29
33.93
32.07
20.49
23.52
22.35
20.1
5.81
9.38
Profit Margin (%)
91
98
128
141
134
105
121
188
206
159
173
182
147
173
156
124
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
6
14
29
43
41
30
LT Debt
211
222
271
314
353
359
389
478
490
462
481
512
491
501
462
431
Total Equity
27
30.79
27.6
23.4
22.92
22.86
21.58
22.93
22.35
19.17
13.49
14.42
14.46
11.43
5.79
5.9
Return on Invested Capital (%)
32.76
37.77
33.4
28.34
26.99
26.18
24.41
25.44
25.41
21.77
13.01
16.49
16.65
13.24
4.22
7.44
Return on Capital (%)
32.72
37.73
33.36
28.28
26.96
26.13
24.34
25.34
25.41
21.77
13.1
16.9
17.43
14.32
4.13
7.17
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.01%
-6.59%
Free Cash Flow
148.66%
288.68%
-4.09%
Net Income, GAAP
-1.76%
1.93%
61.63%
Sales/Revenue/Turnover
1.71%
2.76%
0.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
296
2025
- -
- -
- -
- -
296
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.2
2025
- -
- -
- -
- -
0.32
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -
Business
Victrex plc manufactures and sells high-performance PEEK and PAEK-based polymer solutions, semi-finished and finished parts including pipes, films, fibres, composite tapes and thermoplastic components; offers specialist solutions for medical device manufacturers such as PEEK-OPTIMA for spine, arthroscopy, cranio-maxillofacial, trauma plates, knee implants and drug delivery applications; and provides VICTREX polymers like 450G PEEK, AE 250 for aerospace composites, XPI grades for e-mobility wire coatings and APTIV acoustic films for electronics. The company operates through Sustainable Solutions (encompassing aerospace, automotive, energy & industrial, electronics) and Medical segments, serving customers in automotive, aerospace, energy, electronics, industrial manufacturing & engineering and medical markets across more than 40 countries with facilities in the UK, Europe, North America, China, Japan and other Asian locations. Founded in 1993 and headquartered in Thornton Cleveleys, Lancashire, UK, Victrex focuses on six core markets aligned to global megatrends including climate change and technology breakthroughs; recent developments include new China manufacturing facilities reaching commercial production in late FY2024, Project Vista for sales and Go-to-Market improvements launching in FY2024, key mega-programme milestones such as regulatory submissions for PEEK Knee in India and US clinical trial approval, ongoing Magma collaboration with TechnipFMC and Petrobras for PEEK composite pipes, E-mobility customer expansions across automotive platforms, Trauma revenue exceeding £1m with new Asian customers, Aerospace Composites qualifications advancing for OEM retrofit projects, and Bond 3D impairment alongside US FDA approval for 3D printed Porous PEEK spinal cages in September 2024.

Company News

APIChat
  • Victrex plc (VTXPY) Q2 2026 Earnings Call Transcript

  • Victrex PLC (OTCMKTS:VTXPF) Short Interest Down 81.6% in January

  • Victrex plc (VTXPF) Q4 2025 Earnings Call Transcript

  • Victrex plc (VTXPF) Q3 2025 Sales/ Trading Statement Call Transcript

  • Victrex plc (VTXPF) Q2 2025 Earnings Call Transcript

  • Victrex plc (VTXPF) Q4 2024 Earnings Call Transcript

  • Victrex plc (VTXPF) Q4 2023 Earnings Call Transcript

  • Victrex plc (VTXPF) Q2 2023 Earnings Call Transcript

  • Victrex Has Growth and Value

  • Victrex plc (VTXPF) Q4 2022 Earnings Call Transcript

  • Victrex PLC (VTXPF) CEO Jakob Sigurdsson on Q2 2020 Results - Earnings Call Transcript